SCHEMBL29443917

CC[C@H](C)[C@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)O)C(C)C)[C@@H](C)O)C(C)C

nearest known ligand 0.66

Predicted protein targets (top 7)

	gene	UniProt	supporting neighbours	confidence
▸	CALCR	P30988	3/20	0.66

▸	GLP1R	P43220	14/20	0.65

▸	NPY1R	P25929	1/20	0.64

▸	NPY2R	P49146	1/20	0.64

▸	NPY4R	P50391	1/20	0.64

▸	NPY5R	Q15761	1/20	0.64

▸	CCKBR	P32239	4/20	0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30690369	0.99	CALCR (0.66)	CALCRGLP1RNPY1RNPY2RNPY4R
SCHEMBL30690333	0.99	CALCR (0.66)	CALCRGLP1RNPY1RNPY2RNPY4R
SCHEMBL30658201	0.93	CALCR (0.65)	CALCRGLP1RNPY1RNPY2RNPY4R
SCHEMBL31000908	0.92	NPY2R (0.72)	CALCRGLP1RNPY1RNPY2RNPY4R
SCHEMBL30567706	0.89	GLP1R (0.70)	CALCRGLP1RNPY1RNPY2RNPY4R
SCHEMBL30176434	0.89	CALCR (0.70)	CALCRGLP1RNPY1RNPY2RNPY4R
SCHEMBL31073531	0.89	MAPK8 (0.66)	GLP1RNPY1RNPY2RNPY4RNPY5R
SCHEMBL30176459	0.88	CALCR (0.69)	CALCRGLP1RNPY1RNPY2RNPY4R
SCHEMBL31148884	0.88	CALCR (0.79)	CALCRGLP1RNPY1RNPY2RNPY4R
SCHEMBL30431894	0.88	NPY1R (0.62)	CALCRGLP1RNPY1RNPY2RNPY4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-11806365-B2	Modified T lymphocytes comprising a CD52 antibody-inducible caspase and methods of apoptosis	CELGENE CORPORATION (US)	2023-11-07	—	—	US	disclosed
US-20220324991-A1	BCMA-BINDING ANTIBODIES AND USES THEREOF	CELGENE CORPORATION	2022-10-13	—	—	US	disclosed
US-11401336-B2	BCMA-binding antibodies and uses thereof	CELGENE CORPORATION (US)	2022-08-02	—	—	US	disclosed
US-20220106404-A1	CHIMERIC ANTIGEN RECEPTORS	CELGENE CORPORATION	2022-04-07	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20220324991-A1	BCMA-BINDING ANTIBODIES AND USES THEREOF	CD79B, BCL6, CD22	CALCR 1861/4885GLP1R 4654/4885NPY1R 3799/4885
US-11401336-B2	BCMA-binding antibodies and uses thereof	CD79B, BCL6, CD22	CALCR 1861/4885GLP1R 4654/4885NPY1R 3799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.